

Vital-D Rx™

Get A Little *Sun* ...Inside!

Most ESRD¹ and CKD² patients are 25-hydroxyvitamin D deficient or insufficient.

- Treatment with an active vitamin D analogue does not resolve 25 (OH) D deficiency. -

Low 25(OH) D levels are associated with:

- Cardiovascular disease ³
- Secondary hyperparathyroidism ⁴
- Insulin resistance ⁵
- Metabolic Syndrome ⁶

KDOQI™ recommends treatment of vitamin D deficiency starting with CKD stage 3.

One Vital-D Rx™ per day provides KDOQI's recommendation of 50,000 IU per month.

Vital-D Rx™ is the only CKD/ESRD vitamin with zinc and 1750 IU cholecalciferol (D₃).

Call 1-800-879-4755

for more information or samples

Ingredients:

Cholecalciferol (D₃) 1750 IU
Ascorbic Acid 60 mg
Thiamine 1.5 mg
Riboflavin 1.7 mg
Pyridoxine 10 mg
Cobalamin 6 mcg.
Pantothenic Acid 10 mg
Biotin 300 mcg

Niacinamide 20 mg
Zinc 12.5 mg
Folic Acid 1 mg

Inactive Ingredients:

Microcrystalline Cellulose, Fumed
Silicon Dioxide NF, Stearic Acid,
Croscarmellose Sodium, Magnesium
Stearate NF

Precaution:

Folic Acid may obscure pernicious anemia
or produce remission while neurologic
progress may continue.

Suggested Dosage:

One tablet daily or as directed by the
physician.

Dist by:

NEPHRO-TECH, INC.
Shawnee, KS 66203

© 2007 NEPHRO-TECH, INC.

References:

1. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R.: Vitamin D levels and early mortality among incident hemodialysis patients. *Kidney Int.* 2007 Aug 8; [Epub ahead of print] **2.** LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves KL, Moe SM.: Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. *Am J Kidney Dis.* 2005 Jun;45(6):1026-33 **3.** Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A, Levine B, Mehrotra R, Norris K. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. *Arch Intern Med.* 2007 Jun 11;167(11):1159-65. **4.** Al-Aly Z, Qazi RA, González EA, Zeringue A, Martin KJ.: Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. *Am J Kidney Dis.* 2007 Jul;50(1):59-68 **5.** Chonchol M, Scragg R.: 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. *Kidney Int.* 2007 Jan;71(2):134-9. **6.** Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. *Diabetes Care.* 2005 May;28(5):1228-30.

KDOQI is a registered trademark of the National Kidney Foundation.